Skolnick P
DOV Pharmaceutical, Inc Hackensack, New Jersey 07601, USA.
Amino Acids. 2002;23(1-3):153-9. doi: 10.1007/s00726-001-0121-7.
On a biochemical level, conventional antidepressants have been shown to modulate synaptic levels of biogenic amines (i.e., serotonin, norepinephrine, and dopamine), most often by interfering with reuptake processes or inhibiting metabolism. Strategies directed at modulating glutamatergic transmission may overcome the principal limitations (i.e., delayed onset and low efficacy) that appear to be inherent to these conventional agents. In this brief overview, I summarize two glutamate-based approaches to develop novel antidepressants. These distinct and (on a cellular level) seemingly diametric strategies may converge on intracellular pathways that are also impacted upon by chronic treatment with biogenic amine based agents.
在生化水平上，传统抗抑郁药已被证明可调节生物胺（即血清素、去甲肾上腺素和多巴胺）的突触水平，最常见的方式是干扰再摄取过程或抑制代谢。针对调节谷氨酸能传递的策略可能会克服这些传统药物似乎固有的主要局限性（即起效延迟和疗效低）。在本简要概述中，我总结了两种基于谷氨酸开发新型抗抑郁药的方法。这些不同且（在细胞水平上）看似截然相反的策略可能会汇聚到细胞内途径上，而这些途径也会受到基于生物胺的药物长期治疗的影响。
